Curaleaf Holdings has pushed back against Aurora Cannabis's decision to reject its enhanced acquisition proposal without entering negotiations, arguing the offer represents substantial value for shareholders.
The Massachusetts-based multistate operator said its latest bid carried a 217% premium when the cash component is excluded from the calculation. Aurora's board turned down the proposal without engaging in discussions with Curaleaf.
The rejection marks the latest development in Curaleaf's pursuit of the Canadian licensed producer, which has struggled with profitability despite being one of the country's largest cannabis companies. Aurora's market capitalization has declined sharply from its peak during the Canadian cannabis boom of 2018-2019.
The Valuation Dispute
Curaleaf's pushback centers on how the premium is calculated. By removing cash from the equation, the company argues its offer provides Aurora shareholders with significantly more value than the current stock price suggests. The specific dollar amounts and structure of the enhanced bid were not disclosed in the announcement.
Aurora's board has maintained that the proposal undervalues the company and isn't in the best interests of shareholders. The Edmonton-based company has pointed to its international medical cannabis operations and recent cost-cutting measures as reasons to remain independent.
Cross-Border Complications
The proposed deal faces regulatory hurdles beyond typical M&A scrutiny. U.S. cannabis companies remain federally illegal, creating complications for cross-border transactions with Canadian firms that operate under federal licenses. Curaleaf would need to structure any acquisition carefully to avoid jeopardizing Aurora's international operations, particularly in Germany and other European markets where medical cannabis is legal.
Several Canadian licensed producers have seen their valuations crater since the initial legalization hype. Aurora itself has undergone multiple rounds of layoffs and facility closures as the Canadian market failed to meet early growth projections. The company's international medical business has become increasingly important to its strategy.
What's Next
Curaleaf hasn't indicated whether it will make another offer or take its proposal directly to Aurora shareholders. The U.S. operator has been expanding its international presence and views Aurora's established medical cannabis infrastructure as attractive despite the company's financial challenges.
Aurora shareholders will likely scrutinize management's decision to reject the bid without negotiation, particularly if the stock price remains depressed. The company's next earnings report could influence whether investors pressure the board to reconsider.
The cannabis M&A landscape has shifted dramatically from the consolidation wave of 2021-2022, with fewer deals closing and valuations remaining subdued across both the U.S. and Canadian markets.
This article is based on original reporting by mjbizdaily.com.
